BRM 2019 Program

The BRM 2019 program covers two days of panel discussions, presentations, and networking events. The central theme addressed by our distinguished speakers is "defining and creating value." We will explore how advances in cell and gene therapy, drug development, and bioengineering in regenerative medicine are moving from the lab to the patient — and what it will take to identify real, lasting value for business and society.


Click here for a PDF version of the agenda.


All sessions on July 15–16 are held in Aldrich Hall 112 at Harvard Business School, unless otherwise noted.


July 14


4:00 - 6:00 p.m.

Welcome Reception | Harvard Business School, Spangler Center, Williams Room

George Q. Daley, M.D., Ph.D., Dean of the Faculty of Medicine, Harvard Medical School (remarks begin at 4:30 p.m.)


July 15

Defining Value

8–9 a.m.

Breakfast | Harvard Business School, Aldrich Hall, Room 112

9–9:30 a.m.

Opening Keynote

A shared mission: discovery, development, repeatability, and commercialization in academia and business

Mark Fishman, M.D., Harvard University

9:30–10:15 a.m.

Investing in Talent to Scale Your Company

Sarah Larson, Third Rock Ventures

10:15–10:30 a.m.


10:30–11:30 a.m.


Turning early scientific value into commercial value

Amritha Jaishankar, Ph.D., MD Stem Cell Resesarch Fund
Curtis Keith, Ph.D., Blavatnik Accelerator
Roger Kitterman, Partners Innovation Fund
Keith Thompson, Cell and Gene Catapult

11:30 a.m.–12:30 p.m.


How is value defined by different types of investors?

Amir Nashat, ScD, Polaris Partners
Jason Hafler, Ph.D., Sanofi 
Thomas Needham, M.B.A., Broadview

12:30–1:30 p.m.


1:30–1:40 p.m.


Industry overview

Janet Lambert, Alliance for Regenerative Medicine


1:40-2:25 p.m.


Generating value: what different investors expect

Moderator: Janet Lambert, Alliance for Regenerative Medicine

Whitney Ijem, Guggenheim Securities
Imran Nasrullah, M.S., J.D., C.L.P., Boehringer Ingelheim
Matthew Gall, C.F.A., Sarepta Therapeutics

2:25-2:30 p.m.


Introduction of The ARM Foundation for Cell & Gene Medicine and its economic impact study

David Smith, J.D., Pepper Hamilton LLP

2:30–3:30 p.m.


Measuring value: Developing a macroecnomic model to understand potential impact of cell and gene medicine on healthcare systems

Moderator: Morrie Ruffin, ARM Foundation for Cell & Gene Medicine

Amitabh Chandra, Ph.D., Harvard Business School
John Doyle, Dr.P.H., M.P.H., Pfizer Healthcare Innovation Center   
Michael Sherman, M.D., Harvard Pilgrim Healthcare
Eric Faulkner, M.P.H., Evidera
David Smith, J.D., Pepper Hamilton, LLP

3:30–3:40 p.m.


3:50–4:30 p.m.

Closing Address

Leadership in high-risk environments

Nancy Koehn, Ph.D., Harvard Business School

5–6 p.m.

Reception: Harvard Business School Spangler Center, Williams Room

6–8 p.m.

Dinner: Harvard Business School Spangler Center, Williams Room

Perspectives on disease: researcher and patient advocate

Jayaraj Rajagopal, M.D., Massachusetts General Hospital  
Joan Finnegan Brooks


July 16

Creating Value: Case Studies

8–9 a.m.


9–9:30 a.m.

Opening Address

Tiny Technologies: Big Impact

Sangeeta Bhatia, M.D., Ph.D., Massachusetts Institute of Technology/Brigham and Women's Hospital

9:30–10 a.m.


Suiting technology to business model and financing

Luk Vandenberghe, Ph.D., Massachusetts Eye and Ear

10–10:30 a.m.


The steps from academic studies to SRA to venture incubation to public company

Jason Gardner, Ph.D., Magenta Therapeutics

10:30–10:45 a.m.


10:45–11:15 a.m.


Why replace cells when you can turn them on or off?

Albert Edge, Ph.D., Massachusetts Eye and Ear

11:15–11:45 p.m.


Why use cells when you can use their output?

Steven Stice, Ph.D., ArunA Biomedical, University of Georgia

11:45 a.m.–12:30 p.m.


Value of in vitro models

Vikram Khurana, M.D., Ph.D., Brigham and Women's Hospital, Yumanity
Geraldine Hamilton, Ph.D., Emulate  
Mark Skylar-Scott, Ph.D., Jennifer Lewis Laboratory, Harvard University

12:30–1:30 p.m.


12:45-1:15 p.m.


The Prospects for iPS-based Therapies-The View from the US and Japan
Marcie Glicksman, Ph.D., Orig3n
Hiroto Bando, Ph.D., Fujifilm

1:30–2:45 p.m.


How do biomaterials work with cells and genes to provide better solutions?

Daniel Anderson, Ph.D., Massachusetts Institute of Technology 
Jennifer Elisseeff, Ph.D., Johns Hopkins University
Paula Hammond, Ph.D., Massachusetts Institute of Technology

2:45–3:15 p.m.


The CEO's perspective

Geoffrey MacKay, AVROBIO

3:15–4 p.m.

Closing Address

The future of regenerative medicine: the intersection of genetic engineering and cell therapy

George Church, Ph.D., Harvard Medical School


Page last updated: 7/02/2019